Real‐world lived experience of older adults with type 1 diabetes after an automated insulin delivery trial
Authors' conclusion
Almost 2 years after completing a closed-loop clinical trial, closed-loop automated insulin delivery remains the preferred type 1 diabetes therapy for the majority of older adult participants. Chronological age is not a barrier to real-world successful use of diabetes technology. Identifying age-related barriers, and solutions, to diabetes technology use among older adults is warranted.
Study context
- Population
- Older adults with T1D, pre-existing insulin pump users, who previously completed the OldeR Adult Closed-Loop (ORACL) randomised trial; mean age 70 years (SD 5)
- Participants
- 28 adults
- Outcome
- Continued real-world closed-loop use and lived experience
- Follow-up
- Median 650 days (IQR 608-694) after final ORACL trial visit
Methodological detailssemi-structured interviews, follow-up of ORACL randomised trial participants
- Semi-structured interviews
- Follow-up of ORACL randomised trial participants
Main finding
As reported in the abstract
median 650 days (IQR 608-694) after final ORACL trial visit
Still using a commercial closed-loop system at interview
23
82%
Discontinued
5
Original publication
Real‐world lived experience of older adults with type 1 diabetes after an automated insulin delivery trial. Diabet Med. Published 10 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →